Literature DB >> 3932267

Class II positive human dermal fibroblasts restimulate cloned allospecific T cells but fail to stimulate primary allogeneic lymphoproliferation.

D H Maurer, W E Collins, J H Hanke, M Van, R R Rich, M S Pollack.   

Abstract

Recently, a number of laboratories have shown that gamma interferon (IFN-gamma) is a potent modulator of HLA class II antigen expression in a variety of cell types ranging from classical antigen presenting cells to those not expected to participate in physiological antigen presentation such as fibroblasts. In order to examine the role of HLA class II expressing fibroblasts in antigen presentation, we established dermal fibroblast (FIB) strains from five HLA typed donors. After optimal preculture with IFN-gamma, class II positive FIB were fully competent to restimulate proliferative responses of two DR specific T cell clones and one DP specific T cell line. However, they failed to elicit strong primary allogeneic proliferation from fully DR mismatched fresh PBMC. This failure was not due to a direct suppressive effect of FIB and could not be corrected by exogenous IL1 or by factors contained in conventional mixed leukocyte culture supernatants.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932267     DOI: 10.1016/0198-8859(85)90232-0

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  3 in total

1.  Immunoregulatory properties of bone marrow-derived cells in the iris and ciliary body.

Authors:  J S Williamson; D Bradley; J W Streilein
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

2.  Defective antigen presentation and novel structural properties of DR1 from an HLA haplotype associated with 21-hydroxylase deficiency.

Authors:  J E Davis; R R Rich; M Van; H V Le; M S Pollack; R G Cook
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

3.  Interferon-gamma-dependent immunosuppressive effects of human gingival fibroblasts.

Authors:  Y Shimabukuro; S Murakami; H Okada
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.